The Life Sciences Sector

The life sciences sector is particularly vulnerable to class actions due to its critical role in health and well-being, as well as the potential for significant reputational and financial damage.

In this episode of The Class Actions Chronicles, Henriëtte Kasteel and León Korsten explore:

• Why the life sciences sector is an attractive target for claimants and funders.
• How high-profile cases, such as those involving medical devices and pharmaceutical pricing, highlight the challenges companies face.
• The evolving role of health insurers as plaintiffs and the judiciary's approach to compensation claims.

As case law develops, the risks for companies in this sector will continue to grow.